Over the last few weeks, there has been a lot of coverage of a story involving a new mother from Sacramento. You can read the details of the story here and here. Basically, a new [...]
Perinatal loss is a traumatic event for women and their families. While we clearly understand the potential for perinatal loss to cause significant emotional consequences, we have relatively little data on the prevalence of anxiety [...]
When I meet with mothers of new babies, I often spend a fair amount of time delving into their beliefs about parenting and what they perceive as the “right” way to care for their new [...]
Postpartum depression (PPD) screening has been increasingly implemented not only in obstetric, but also in primary care and pediatric settings, over the past decade. While there is a growing appreciation for the prevalence of [...]
We know that about 15% of women suffer from postpartum depression (PPD). But what is less clear is how to reliably identify women with PPD and to then ensure that they get the support and [...]
We are very pleased to announce the release of the MGH Perinatal Depression Scale available free of charge on the App Store (https://appsto.re/us/-3X4jb.i). The MGHPDS smartphone app includes digital versions of perinatal depression screening tools [...]
Over the last decade, there has been increased interest around the country in establishing consistent screening for perinatal depression across a range of clinical settings. Approximately 40 states have instituted guidelines and recommendations regarding screening [...]
While many women are at risk for postpartum depression, we continue to struggle in providing adequate support and care to women in this setting, especially socioeconomically disadvantaged women. In a randomized clinical trial including [...]
It is clear that screening for perinatal depression substantially improves detection; however, screening alone does not appear to improve rates of treatment or outcomes. What we find is that many, if not most, women with [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression. SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. This drug was initially under [...]
